| Sitemap | Subscribe | Contact Us | ||
|
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
Latest Type 2 Articles
It May Be a Matter of Where You Store Your Fat
Whether or not you get fat is not the critical factor in developing type 2 diabetes, according to a recent mouse study by Texas researchers; instead, it's where that fat is packed away.
Obese mice that were genetically engineered to store fat only in fat tissue became very fat indeed, but they did not develop insulin resistance or type 2 diabetes. Why? Because they did not accumulate fat in non-fat tissues such as their liver, heart, or muscles.
The subject mice were altered to produce an excess of adiponectin, a beneficial hormone produced by fat tissue, and a deficiency of leptin, a hormone that suppresses appetite. Adiponectin is usually secreted in an inverse relationship to fat: the fatter one is, the less adiponectin is secreted. In these specially engineered mice, however, adiponectin secretion was high no matter what.
Without the appetite-suppressing action of leptin, the mice overate and became extremely obese. However, they didn't get type 2 diabetes because the adiponectin caused all their extra fat calories to be properly stored in subcutaneous fat tissue instead of in their liver, heart, or muscle tissue.
The researchers report that adiponectin acts as a starvation signal which tells the body that its fat tissue is ready and willing to store more fat. In people who can't appropriately store their fat where it belongs, insulin resistance is the result. The scientists believe that this finding explains why some obese people don't get type 2 diabetes and why some relatively lean people do.
Sources: Medline Plus; Journal of Clinical Investigation, August 2007
18 comments - 1 May 2008
17 comments - 1 May 2008
10 comments - 21 Apr 2008
7 comments - 28 Apr 2008
Comments...
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register..
Register your Diabetes Health Username here.
The article is actually very helpful as it helps to get a target to certain patient populations. For example TZD's shift fat from visceral organs to the subcutaneous tissue and may be more benificial in these non-obese individuals and it confirms other agents may be better in obese individuals. It also helps to provide proof of concept for many medications being researched.
However, some of the information may be well known by some endocrinologists already.
Have Your Say...